PMID- 17598007
OWN - NLM
STAT- MEDLINE
DCOM- 20070905
LR  - 20070628
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 98
IP  - 1
DP  - 2007 Jul
TI  - Heparin induces mobilization of osteoprotegerin into the circulation.
PG  - 148-54
AB  - Heparin treatment may induce osteoporosis by an unknown mechanism. 
      Osteoprotegerin (OPG), a glycoprotein with a heparin-binding site, is a decoy 
      receptor for RANKL which is responsible for osteoclast development. The objective 
      was to investigate the effect of unfractionated heparin (UFH) and 
      lowmolecular-weight heparin (LMWH; dalteparin) on plasma levels of OPG. 
      Twenty-two male students were allocated to the following treatment regimens; A) 
      one bolus of 5,000 IU UFH iv followed by infusion of 450 IU/kg/24 h for 72 hours 
      (n = 7), B) sc administration of LMWH (200 IU/kg) once daily for 72 hours (n = 
      8), C) sc administration of 100 IU/kg LMWH once (n = 8), D) sc administration of 
      250 IU/kg UFH once (n = 7), E) control infusion of saline for 12 hours (n = 7). 
      UFH boluses of 5,000 IU were given 4 and 24 hours after cessation of regimens A 
      and B. Bolus injection of UFH iv caused a prompt increase in plasma OPG from 0.68 
      ng/ml (SD = 0.09) to 1.13 ng/ml (SD = 0.30) (p = 0.003) which declined during the 
      continuous UFH infusion and reached baseline values after 8 hours (regime A). 
      Similar increases in plasma OPG was obtained by repeated UFH boluses after 
      cessation of treatment. Subcutaneous administration of LMWH (200 IU/kg) caused a 
      modest, but significant (p = 0.002) increase in plasma OPG similar to the 
      mobilization by 250 IU/kg UFH sc, but the LMWH treatment caused a three-fold 
      higher anti-Xa activity (p < 0.001). We conclude that UFH causes a more 
      pronounced vascular mobilization of OPG than LMWH, indicating that UFH has a 
      higher affinity for OPG than LMWH.
FAU - Vik, Anders
AU  - Vik A
AD  - Center for Atherothrombotic Research in Tromso (CART), Department of Medicine, 
      Institute of Clinical Medicine, University of Tromso, N-9037 Tromso, Norway. 
      anders.vik@fagmed.uit.no
FAU - Brodin, Ellen
AU  - Brodin E
FAU - Sveinbjornsson, Baldur
AU  - Sveinbjornsson B
FAU - Hansen, John-Bjarne
AU  - Hansen JB
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Osteoprotegerin)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Adult
MH  - Blood Circulation
MH  - Drug Administration Routes
MH  - Heparin/administration & dosage/*adverse effects
MH  - Heparin, Low-Molecular-Weight/administration & dosage/adverse effects
MH  - Humans
MH  - Male
MH  - Osteoporosis/chemically induced
MH  - Osteoprotegerin/*blood/pharmacokinetics
MH  - Pharmacokinetics
EDAT- 2007/06/29 09:00
MHDA- 2007/09/06 09:00
CRDT- 2007/06/29 09:00
PHST- 2007/06/29 09:00 [pubmed]
PHST- 2007/09/06 09:00 [medline]
PHST- 2007/06/29 09:00 [entrez]
AID - 07070148 [pii]
PST - ppublish
SO  - Thromb Haemost. 2007 Jul;98(1):148-54.